Mechanism of inhibition defi nes CETP activity: A mathematical model for CETP in vitro

Journal of Lipid Research

Volumn 50, Issue 11, 2009, Pages 2222-2234

  Potter, Laura K ^a,b   Sprecher, Dennis L ^a   Walker, Max C ^a   Tobin, Frank L ^a  

^a GLAXOSMITHKLINE   (United States)

^b SYNGENTA BIOTECHNOLOGY INC   (United States)

Author keywords

CETP inhibitors; Cholesteryl ester transfer protein; Lipemia; Lipoprotein metabolism; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINOLINE DERIVATIVE; THIOL DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CALIBRATION; IN VITRO STUDY; LIPID TRANSPORT; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; PARTICLE SIZE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SIMULATION; ALGORITHM; ANIMAL; BINDING SITE; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG ANTAGONISM; HUMAN; KINETICS; METABOLISM;

ALGORITHMS; ANIMALS; ANTICHOLESTEREMIC AGENTS; BINDING SITES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; COMPUTER SIMULATION; HUMANS; KINETICS; MODELS, BIOLOGICAL; QUINOLINES; SULFHYDRYL COMPOUNDS; TRIGLYCERIDES;

EID: 70350366589     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M900015-JLR200     Document Type: Article

References (44)

1. Barter, P. J. 2002. Hugh Sinclair lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl. 3: 39-47.
2. Yamashita, S., and Y. Matsuzawa. 1999. Cholesteryl ester transfer protein. In Lipoproteins in Health and Disease. D. J. Betteridge, D. R. Illingworth, and J. Shepherd, editors. Arnold, London. 277-299.
3. de Grooth, G. J., A. H. Klerkx, E. S. Stroes, A. F. Stalenhoef, J. J. Kastelein, and J. A. Kuivenhoven. 2004. A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45: 1967-1974.
4. Soutar, A. K. 1999. Low-density lipoprotein receptors. In Lipoproteins in Health and Disease. D. J. Betteridge, D. R. Illingworth, and J. Shepherd, editors. Arnold, London. 303-322.
5. Rader, D. J. 2003. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 92: 42J-49J.
6. Barter, P. J., and J. J. Kastelein. 2006. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J. Am. Coll. Cardiol. 47: 492-499.
7. Athyros, V. G., D. P. Mikhailidis, A. I. Kakafika, A. Karagiannis, A. Hatzitolios, K. Tziomalos, E. S. Ganotakis, E. N. Liberopoulos, and M. Elisaf. 2007. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr. Drug Targets. 8: 483-488.
8. Dullaart, R. P., G. M. Dallinga-Thie, B. H. Wolffenbuttel, and A. van Tol. 2007. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur. J. Clin. Invest. 37: 90-98.
9. Barter, P. J., M. Caulfi eld, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 357: 2109-2122.
10. Nicholls, S. J., D. M. Brennan, K. Wolski, S. R. Kalidindi, K.-W. Moon, E. M. Tuzcu, and S. E. Nissen. 2007. Abstract 684: Changes in levels of high density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: insights from ILLUSTRATE. Circulation 116: II_127-b-.
11. Tall, A. R., L. Yvan-Charvet, and N. Wang. 2007. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler. Thromb. Vasc. Biol. 27: 257-260.
12. Guerin, M., P. J. Dolphin, and M. J. Chapman. 1994. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler. Thromb. 14: 199-206.
13. Murakami, T., S. Michelagnoli, R. Longhi, G. Gianfranceschi, F. Pazzucconi, L. Calabresi, C. R. Sirtori, and G. Franceschini. 1995. Triglycerides are major determinants of cholesterol esterification/ transfer and HDL remodeling in human plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1819-1828.
14. Le, N. A., W. Innis-Whitehouse, X. Li, R. Bakker-Arkema, D. Black, and W. V. Brown. 2000. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism. 49: 167-177.
15. Guerin, M., P. Egger, C. Soudant, W. Le Goff, A. van Tol, R. Dupuis, and M. J. Chapman. 2002. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J. Lipid Res. 43: 1652-1660.
16. Guerin, M., W. Le Goff, T. S. Lassel, A. Van Tol, G. Steiner, and M. J. Chapman. 2001. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21: 282-288.
17. Tall, A., D. Sammett, and E. Granot. 1986. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia. J. Clin. Invest. 77: 1163-1172.
18. Lahdenpera, S., M. Syvanne, J. Kahri, and M. R. Taskinen. 1996. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia. 39: 453-461.
19. Guerin, M., P. J. Dolphin, and M. J. Chapman. 1994. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler. Thromb. 14: 679-685.
20. Barter, P., and K. A. Rye. 1994. Cholesteryl ester transfer protein: its role in plasma lipid transport. Clin. Exp. Pharmacol. Physiol. 21: 663-672.
21. Tall, A. R. 1993. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34: 1255-1274.
22. Swenson, T. L., R. W. Brocia, and A. R. Tall. 1988. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J. Biol. Chem. 263: 5150-5157.
23. Ihm, J., D. M. Quinn, S. J. Busch, B. Chataing, and J. A. Harmony 1982. Kinetics of plasma protein-catalyzed exchange of phosphatidylcholine and cholesteryl ester between plasma lipoproteins. J. Lipid Res. 23: 1328-1341.
24. Qiu, X., A. Mistry, M. J. Ammirati, B. A. Chrunyk, R. W. Clark, Y. Cong, J. S. Culp, D. E. Danley, T. B. Freeman, K. F. Geoghegan et al. 2007. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat. Struct. Mol. Biol. 14: 106-113.
25. Connolly, D. T., J. McIntyre, D. Heuvelman, E. E. Remsen, R. E. McKinnie, L. Vu, M. Melton, R. Monsell, E. S. Krul, and K. Glenn 1996. Physical and kinetic characterization of recombinant human cholesteryl ester transfer protein. Biochem. J. 320: 39-47.
26. Barter, P. J., G. J. Hopkins, L. Gorjatschko, and M. E. Jones. 1982. A unified model of esterified cholesterol exchanges between human plasma lipoproteins. Atherosclerosis. 44: 27-40.
27. Barter, P. J., and M. E. Jones. 1980. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J. Lipid Res. 21: 238-249.
28. Ko, K. W., T. Ohnishi, and S. Yokoyama. 1994. Triglyceride transfer is required for net cholesteryl ester transfer between lipoproteins in plasma by lipid transfer protein. Evidence for a hetero-exchange transfer mechanism demonstrated by using novel monoclonal antibodies. J. Biol. Chem. 269: 28206-28213.
29. Morton, R. E., and D. J. Greene. 2003. The surface cholesteryl ester content of donor and acceptor particles regulates CETP: a liposome-based approach to assess the substrate properties of lipoproteins. J. Lipid Res. 44: 1364-1372.
30. Morton, R. E., and D. B. Zilversmit. 1983. Inter-relationship of lipids transferred by the lipid-transfer protein isolated from human lipoprotein-defi cient plasma. J. Biol. Chem. 258: 11751-11757.
31. Serdyuk, A. P., and R. E. Morton. 1997. Lipid transfer inhibitor protein activity deficiency in normolipidemic uremic patients on continuous ambulatory peritoneal dialysis. Arterioscler. Thromb. Vasc. Biol. 17: 1716-1724.
32. Barter, P. J., L. B. Chang, and O. V. Rajaram. 1990. Sodium oleate dissociates the heteroexchange of cholesteryl esters and triacylglycerol between HDL and triacylglycerol-rich lipoproteins. Biochim. Biophys. Acta. 1047: 294-297.
33. Van Tol, A., L. M. Scheek, and J. E. Groener. 1991. Net mass transfer of cholesteryl esters from low density lipoproteins to high density lipoproteins in plasma from normolipidemic subjects. Arterioscler. Thromb. 11: 55-63.
34. Barter, P. J., L. B. Chang, and O. V. Rajaram. 1990. Sodium oleate promotes a redistribution of cholesteryl esters from high to low density lipoproteins. Atherosclerosis. 84: 13-24.
35. Liang, H. Q., K. A. Rye, and P. J. Barter. 1994. Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins. J. Lipid Res. 35: 1187-1199.
36. Serdyuk, A. P., and R. E. Morton. 1999. Lipid transfer inhibitor protein defines the participation of lipoproteins in lipid transfer reactions: CETP has no preference for cholesteryl esters in HDL versus LDL. Arterioscler. Thromb. Vasc. Biol. 19: 718-726.
37. Deckelbaum, R. J., S. Eisenberg, Y. Oschry, E. Butbul, I. Sharon and T. Olivecrona. 1982. Reversible modification of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J. Biol. Chem. 257: 6509-6517.
38. Shampine, L., and M. Reichelt. 1997. The MATLAB ODE Suite. SIAM J. Sci. Comput. 18: 1-22.
39. Vogel, C. R. 2002. Computational methods for inverse problems. SIAM, Philadelphia.
40. Deckelbaum, R. J., S. Eisenberg, Y. Oschry, E. Granot, I. Sharon, and G. Bengtsson-Olivecrona. 1986. Conversion of human plasma high density lipoprotein-2 to high density lipoprotein-3. Roles of neutral lipid exchange and triglyceride lipases. J. Biol. Chem. 261: 5201-5208.
41. Fukasawa, M., H. Arai, and K. Inoue. 1992. Establishment of anti-human cholesteryl ester transfer protein monoclonal antibodies and radioimmunoassaying of the level of cholesteryl ester transfer protein in human plasma. J. Biochem. 111: 696-698.
42. Morton, R. E. 1985. Binding of plasma-derived lipid transfer protein to lipoprotein substrates. The role of binding in the lipid transfer process. J. Biol. Chem. 260: 12593-12599.
43. Wang, X., D. M. Driscoll, and R. E. Morton. 1999. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J. Biol. Chem. 274: 1814-1820.
44. Lagarias, J. C., J. A. Reeds, M. H. Wright, and P. E. Wright. 1998 Convergence properties of the Nelder-Mead simplex method in low dimensions. SIAM J. Optim. 9: 112-147.